OTLK Outlook Therapeutics, Inc.
Listings ·
Nasdaq says OTLK closed under $1.00 for 30 straight business days. The company has until March 24, 2027 to cure, and its latest 10-Q carried a going-concern warning.
The New Jersey court dismissed the second amended complaint in part on Dec. 23, 2025, and plaintiffs refiled. Outlook and certain unnamed officers are defendants; a Delaware derivative suit is stayed.
Outlook says it cannot file its quarterly report on time because of its size, finance department turnover and work on a public offering that closed on August 14, 2026. It has a going concern warning in its last annual report.
Nasdaq says Outlook's stock closed below $1.00 for 30 consecutive business days. The notice has no immediate effect on its Nasdaq Capital Market listing, and a second 180-day period may be available.
| Line | FY ended Sep 30, 2025 | FY ended Sep 30, 2024 |
|---|---|---|
| Research and development | $27.2 million | $41.8 million |
| Net income (loss) | -$62.4 million | -$75.4 million |
| Cash from operations | -$51.8 million | -$68.8 million |
| Cash and equivalents | $8.1 million | $14.9 million |
Opinion Medium conviction
LYTENAVA is approved and the market values it at about $97 million. We think Outlook must sell more stock at a discount before US sales can prove the launch, so we rate the shares Underperform.
Our latest story on this, dated Aug 18, 2026: "Outlook Therapeutics faces securities class action and stayed derivative suit over LYTENAVA BLA". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Sep 25, 2026: "Outlook Therapeutics gets a Nasdaq bid-price notice weeks after its drug's approval". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Aug 17, 2026: "Outlook Therapeutics files NT 10-Q for June quarter, cites finance staff turnover". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Sep 25, 2026: "Outlook Therapeutics gets a Nasdaq bid-price notice weeks after its drug's approval". The story links the filing or release it is based on. Read the story.
Outlook Therapeutics, Inc. trades under the ticker OTLK on NASDAQ.
Outlook Therapeutics, Inc. is listed on NASDAQ. Our directory also records these other listings: DUS:41O; FWB:41O; GETTEX:41O; HAM:41O; HAN:41O; LS:A4046T; LSX:A4046T; MUN:41O; SWB:41O; TRADEGATE:41O; XETR:41O.
The SEC Central Index Key (CIK) for Outlook Therapeutics, Inc. is 1649989. Its filings are on SEC EDGAR.
243,447,554 shares as of 2026-08-14, per the cover page of its 10-Q filed 2026-08-18.
Our directory records Outlook Therapeutics, Inc. under United States.
Our directory classifies Outlook Therapeutics, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Outlook Therapeutics, Inc. is US69012T3059.
aibio.space lists Outlook Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Outlook Therapeutics, Inc. reported a net loss of $62.4 million for the fiscal year ended Sep 30, 2025, and used $51.8 million of cash in operations, per its annual report to the SEC.
$27.2 million in the fiscal year ended Sep 30, 2025, per its annual report.
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). Source
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 8-K (Items 2.02,8.01,9.01). Source
Filed a final prospectus for a securities offering. SEC Form 424B5. Source
Reported a reverse stock split. SEC Form 8-K (Items 5.03,5.07,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Reported a financing. SEC Form 8-K (Items 8.01,9.01). Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported a financing. SEC Form 8-K (Items 1.01,1.02,2.02,9.01). Source
Reported an unregistered sale of its securities. SEC Form 424B5. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). Source
Filed a final prospectus for a securities offering. SEC Form 424B5. Source
Reported the end of a material agreement. SEC Form 8-K (Items 1.02,5.03,5.07,9.01). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Reported a financing. SEC Form 8-K (Items 1.01,2.03,3.02,5.02,9.01). Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-K. Source
Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.05). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio